Skip Navigation

Cardiovascular Research 2002 54(3):485-491; doi:10.1016/S0008-6363(02)00284-5
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Erdös, E. G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erdös, E. G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Kinins, the long march—A personal view

Ervin G Erdös*

University of Illinois College of Medicine at Chicago, Department of Pharmacology (MC 868) 835 S. Wolcott Ave., Room E403 MSA, Chicago, IL 60612-7344, USA

egerdos@uic.edu

* Tel.: +1-312-996-9146; fax: +1-312-996-1648

Received 4 February 2002; accepted 6 February 2002

The first 150 words of the full text of this article appear below.

"Science betokens the most complete renunciation of the pleasure-principle of which our minds are capable."1 Sigmund Freud.

"Oh boy, was he wrong!"2

When asked to write a review article for Cardiovascular Research, I was not sure what the aim of such an endeavor should be. To make a complete list of reports on kinins and kallikreins by now could overload even the hard drive of a computer. A review article on hypotensive peptides in 1966 cited over 600 references and another one in 1968 on bradykinin alone listed 897 ones [1]. Should this brief review be very selective in quoting contributions or a jeremiad of all the near and not-so-near misses made in research? Then I realized that the stated aim of this series of articles is to reflect on how some major research findings were made—in my case, in the field of peptides and peptidases—or maybe how some . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
A. M. Marney, J. Ma, J. M. Luther, T. A. Ikizler, and N. J. Brown
Endogenous Bradykinin Contributes to Increased Plasminogen Activator Inhibitor 1 Antigen following Hemodialysis
J. Am. Soc. Nephrol., October 1, 2009; 20(10): 2246 - 2252.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Zhang, F. Tan, Y. Zhang, and R. A. Skidgel
Carboxypeptidase M and Kinin B1 Receptors Interact to Facilitate Efficient B1 Signaling from B2 Agonists
J. Biol. Chem., March 21, 2008; 283(12): 7994 - 8004.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
G. P. Van Guilder, M. Pretorius, J. M. Luther, J. B. Byrd, K. Hill, J. V. Gainer, and N. J. Brown
Bradykinin Type 2 Receptor BE1 Genotype Influences Bradykinin-Dependent Vasodilation During Angiotensin-Converting Enzyme Inhibition
Hypertension, February 1, 2008; 51(2): 454 - 459.
[Abstract] [Full Text] [PDF]